Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06419608 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety Study of BHV-7000 Monotherapy in Major Depression
A Phase 2 study, sponsored by Biohaven Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 336
- Enrollment target
NCT06419608: Completed Phase 2 study, sponsored by Biohaven Therapeutics.
NCT06419608 is a Phase 2 study that has completed, run by Biohaven Therapeutics. The registered enrollment target is 336 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (153% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06419608, a Phase 2 study, has completed, sponsored by Biohaven Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 336 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the efficacy and safety of BHV-7000 in participants with Major Depressive Disorder (MDD)
Primary Outcome
The MADRS is a clinician- rated scale to assess depressive symptoms which consists of 10 items. Each item is scored on 7-point scale (0 \[absence of symptoms\] to 6 \[severe\]). A higher score represents a higher severity of the level of depression (total scores range from 0 to 60).
Interventions
- DRUG Placebo
- DRUG BHV-7000
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 336 participants |
| Start Date | 2024-05-28 |
| Est. Completion | 2025-11-07 |
| Phase | Phase 2 |
What the finished NCT06419608 record still lists
NCT06419608 is an interventional study that assigns participants to a tested intervention. The registered 336 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (153% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06419608 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06419608 about?
NCT06419608 is a clinical study titled "Efficacy and Safety Study of BHV-7000 Monotherapy in Major Depression". The purpose of this study is to determine the efficacy and safety of BHV-7000 in participants with Major Depressive Disorder (MDD)
What is the current status of trial NCT06419608?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 336 participants. The study started on 2024-05-28. Estimated completion is 2025-11-07.
What interventions are being tested in trial NCT06419608?
The interventions under investigation include: Placebo (DRUG), BHV-7000 (DRUG).
Who is sponsoring clinical trial NCT06419608?
This trial is sponsored by Biohaven Therapeutics, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06419608's enrollment target sits among peer trials
336 141st of 2000 higher than 1,859 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03947385 · 336 participants · Phase 1
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
- NCT03977207 · 336 participants · NA
A Randomized Controlled Trial of Thyroid Hormone Supplementation in Hemodialysis Patients
- NCT04665206 · 336 participants · Phase 1
Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors
- NCT05124457 · 336 participants · Phase 2
DETERMINE: Detemir vs NPH
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI